The GuangYuYuan Chinese Herbal Medicine Co., Ltd., a prominent player in the health care sector, has been making significant strides in the pharmaceutical industry. Based in Xi’an, China, the company specializes in the development and manufacturing of a diverse range of pharmaceutical products. These include Chinese raw material medicines, Western raw material medicines, tablets, capsules, injections, and other drug formulations. In addition to its core pharmaceutical operations, GuangYuYuan also offers advertising services, enhancing its market presence and outreach.
Listed on the Shanghai Stock Exchange, GuangYuYuan has established itself as a key entity in the pharmaceutical landscape. The company’s stock performance has been noteworthy, with a close price of 19.24 CNY as of October 30, 2025. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of 22.92 CNY on August 17, 2025, and a 52-week low of 16.21 CNY on April 6, 2025. These figures reflect the dynamic nature of the pharmaceutical market and the company’s resilience in navigating these changes.
Founded on October 16, 1996, GuangYuYuan has a long-standing history in the industry, marked by its commitment to innovation and quality. The company’s strategic focus on both traditional Chinese medicine and Western pharmaceuticals positions it uniquely in the market, catering to a broad spectrum of healthcare needs. This dual approach not only underscores its versatility but also its dedication to integrating diverse medical practices.
GuangYuYuan’s operations are supported by a robust infrastructure in Xi’an, which serves as the hub for its research, development, and manufacturing activities. The company’s website, www.guangyuyuan.cn , provides comprehensive information about its products, services, and corporate initiatives, serving as a valuable resource for stakeholders and customers alike.
As GuangYuYuan continues to expand its product portfolio and enhance its service offerings, it remains a significant contributor to the health care sector in China and beyond. Its ongoing efforts to innovate and adapt to market demands are likely to sustain its growth trajectory and reinforce its position as a leader in the pharmaceutical industry.
